Veloxis Pharmaceuticals Envarsus Granted Orphan Drug Status by FDA for Kidney Transplant Rejection Prophylaxis

27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.

Veloxis Pharmaceuticals (OTC: VLCYF), today announced that Envarsus® was granted Orphan Drug status by the U.S. Food and Drug Administration (FDA) for prophylaxis of organ rejection in patients receiving allogenic kidney transplants. The designation is to encourage the development of drugs that may provide significant benefit to patients suffering from rare diseases. Envarsus® is Veloxis' once-daily formulation of tacrolimus employing the company's proprietary MeltDose® technology.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

See full press release